A rendering of the Bio-Pharmaceutical Innovation Park in the Wuhan Economic & Technological Development Zone. [Photo/WeChat account: whkfq]
On Nov 29, a groundbreaking ceremony marked the commencement of construction on the Bio-Pharmaceutical Innovation Park in the Wuhan Economic & Technological Development Zone (WEDZ).
The 512-million-yuan ($70.21 million) park will feature comprehensive R&D and international exchange buildings, pharmaceutical R&D incubation facilities, product exhibition spaces, dining areas, and various commercial and activity-supporting amenities. It is slated for completion in October 2026.
The park aims to serve as a high-level research and innovation incubation platform, attract companies from the bio-pharmaceutical industrial chain, and offer comprehensive park services and industrial fund support, positioning itself as a leading bio-pharmaceutical innovation hub in China.
The park was funded by Hiteck Biopharmaceutical Co, a high-tech biopharmaceutical listed company, and is dedicated to the research and production of drugs for neurological and oncological applications. It has already independently developed three Class 1 new biological drugs in China.
